Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.

Kacew AJ, Harris EJ, Lorch JH, Haddad RI, Chau NG, Rabinowits G, LeBoeuf NR, Schmults CD, Thakuria M, MacConaill LE, Hanna GJ.

Eur J Cancer. 2019 Apr 4;113:1-9. doi: 10.1016/j.ejca.2019.03.004. [Epub ahead of print]

PMID:
30954880
2.

Management of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical Guidelines.

Trinh S, Le A, Gowani S, La-Beck NM.

Asia Pac J Oncol Nurs. 2019 Apr-Jun;6(2):154-160. doi: 10.4103/apjon.apjon_3_19. Review.

3.

Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.

Lee HT, Lee SH, Heo YS.

Molecules. 2019 Mar 26;24(6). pii: E1190. doi: 10.3390/molecules24061190. Review.

4.

Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.

Ogata D, Tsuchida T.

Curr Treat Options Oncol. 2019 Mar 14;20(4):30. doi: 10.1007/s11864-019-0629-2. Review.

PMID:
30874952
5.

Immune Checkpoint Inhibitors for Treating Advanced Cutaneous Squamous Cell Carcinoma.

Patel R, Chang ALS.

Am J Clin Dermatol. 2019 Feb 8. doi: 10.1007/s40257-019-00426-w. [Epub ahead of print]

PMID:
30737731
6.

[What's new in oncodermatology?]

Robert C.

Ann Dermatol Venereol. 2018 Dec;145 Suppl 7:VIIS40-VIIS46. doi: 10.1016/S0151-9638(18)31288-2. French.

PMID:
30583756
7.

Antibodies to watch in 2019.

Kaplon H, Reichert JM.

MAbs. 2019 Feb/Mar;11(2):219-238. doi: 10.1080/19420862.2018.1556465. Epub 2018 Dec 22.

8.

Cemiplimab: First Global Approval.

Markham A, Duggan S.

Drugs. 2018 Nov;78(17):1841-1846. doi: 10.1007/s40265-018-1012-5.

PMID:
30456447
9.

Cemiplimab Approved for Treatment of CSCC.

[No authors listed]

Cancer Discov. 2018 Dec;8(12):OF2. doi: 10.1158/2159-8290.CD-NB2018-140. Epub 2018 Oct 30.

PMID:
30377167
10.

Cemiplimab.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

11.

Cemiplimab Achieves Responses in Cutaneous Squamous Cell Carcinoma.

[No authors listed]

Cancer Discov. 2018 Aug;8(8):OF12. doi: 10.1158/2159-8290.CD-RW2018-100. Epub 2018 Jun 22.

PMID:
29934319
12.

Cemiplimab effective in cutaneous SCC.

Sidaway P.

Nat Rev Clin Oncol. 2018 Aug;15(8):472. doi: 10.1038/s41571-018-0056-5. No abstract available.

PMID:
29921845
13.

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG.

N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.

14.

Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.

Minion LE, Tewari KS.

Gynecol Oncol. 2018 Mar;148(3):609-621. doi: 10.1016/j.ygyno.2018.01.009. Epub 2018 Feb 3. Review.

PMID:
29666026
15.

Antibodies to watch in 2018.

Kaplon H, Reichert JM.

MAbs. 2018 Feb/Mar;10(2):183-203. doi: 10.1080/19420862.2018.1415671. Epub 2018 Jan 16.

16.

Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm.

Ghanem S, Valecha GK, Hossri S, Ibrahim U, Atallah JP.

Expert Opin Investig Drugs. 2017 Dec;26(12):1317-1319. doi: 10.1080/13543784.2017.1395019. Epub 2017 Oct 24. No abstract available.

PMID:
29046065
17.

Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice.

Burova E, Hermann A, Waite J, Potocky T, Lai V, Hong S, Liu M, Allbritton O, Woodruff A, Wu Q, D'Orvilliers A, Garnova E, Rafique A, Poueymirou W, Martin J, Huang T, Skokos D, Kantrowitz J, Popke J, Mohrs M, MacDonald D, Ioffe E, Olson W, Lowy I, Murphy A, Thurston G.

Mol Cancer Ther. 2017 May;16(5):861-870. doi: 10.1158/1535-7163.MCT-16-0665. Epub 2017 Mar 6.

18.

Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.

Falchook GS, Leidner R, Stankevich E, Piening B, Bifulco C, Lowy I, Fury MG.

J Immunother Cancer. 2016 Nov 15;4:70. doi: 10.1186/s40425-016-0176-3. eCollection 2016.

Supplemental Content

Loading ...
Support Center